BioMarin Pharmaceutical Inc. and Amicus Therapeutics announced an acquisition agreement where BioMarin will acquire Amicus for $4.8 billion.
The transaction includes gaining Galafold for Fabry Disease and Pombiliti + Opfolda for Pompe Disease, adding high-growth products with $599 million in revenue over the past four quarters.
The acquisition is expected to accelerate revenue growth, diversify the commercial portfolio, and create substantial shareholder value.
Revenue Acceleration
Expected increase in BioMarin's revenue growth with the acquisition of high-growth products like Galafold and Pombiliti + Opfolda.
Portfolio Diversification
Addition of two new treatments to BioMarin's existing portfolio targeting lysosomal storage disorders.
Shareholder Value
The transaction is anticipated to create significant value for shareholders through expanding access to innovative therapies.
- The acquisition will enhance BioMarin's rare disease product portfolio by adding transformative medicines like Galafold and Pombiliti + Opfolda.
- Both companies' dedication to rare diseases will result in reaching more patients globally with life-changing treatments.
- The agreement is expected to accelerate progress in the rare disease community by enhancing resources and scale for delivering medicines.
The acquisition of Amicus Therapeutics by BioMarin Pharmaceutical Inc. marks a strategic move to strengthen their presence in the rare disease market, accelerate revenue growth, and provide innovative therapies to more patients worldwide.